- Home
- ROIV vs EXLS Comparison
ROIV vs EXLS Comparison
Compare ROIV & EXLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | EXLS |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 6.9B |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | ROIV | EXLS |
|---|---|---|
| Price | $21.87 | $41.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $24.31 | ★ $54.50 |
| AVG Volume (30 Days) | ★ 8.3M | 1.1M |
| Earning Date | 02-09-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.94 |
| EPS | N/A | ★ 1.48 |
| Revenue | $20,329,000.00 | ★ $2,026,490,000.00 |
| Revenue This Year | N/A | $15.32 |
| Revenue Next Year | $741.42 | $11.27 |
| P/E Ratio | ★ N/A | $27.84 |
| Revenue Growth | N/A | ★ 14.43 |
| 52 Week Low | $8.73 | $37.30 |
| 52 Week High | $23.47 | $52.43 |
Technical Indicators
Market Signals| Indicator | ROIV | EXLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 45.64 |
| Support Level | $21.36 | $43.03 |
| Resistance Level | $22.72 | $43.67 |
| Average True Range (ATR) | 0.72 | 0.65 |
| MACD | -0.13 | -0.10 |
| Stochastic Oscillator | 32.69 | 12.15 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EXLS ExlService Holdings Inc.
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.